Tip: Folic Acid Prevents Nitroglycerin-Induced Nitric Oxide Synthase Dysfunction
Note that
this study says:
In healthy humans, continuous treatment with nitroglycerin (GTN) causes nitric oxide synthase dysfunction, probably through the reduced bioavailability of tetrahydrobiopterin.
Recent studies proposed that folic acid is involved in the regeneration of tetrahydrobiopterin in different disease states. Therefore, we investigated whether folic acid administration would prevent this phenomenon. We also sought to determine if folic acid supplementation could prevent the development of tolerance to GTN.
And the study concludes:
Our data demonstrate that supplemental folic acid prevents both nitric oxide synthase dysfunction induced by continuous GTN and nitrate tolerance in the arterial circulation of healthy volunteers. We hypothesize that the reduced bioavailability of tetrahydrobiopterin is involved in the pathogenesis of both phenomena. Our results confirm the view that oxidative stress contributes to nitrate tolerance.
And
this study demonstrates that folic acid reverses the endothelial dysfunction induced by BH4 depletion.
More info on BH4 as an essential cofactor for the activation of nitric oxide synthase is found in this
article. The article mentions that methylfolate (L-5-MTHF) may help substitute for BH4 when BH4 is deficient.
So folic acid and BH4 supplementation may help nitroglycerin regain its vasodilating effect. You can buy BH4 in 2.5 mg capsules at these places:
1,
2,
3,
4. But 2.5 mg is quite low compared to the 100 mg found in the prescription BH4 medication called Kuvan. I understand that BH4 is sensitive to degradation by free radicals, so you would be advised to take antioxidants when you take BH4.
By the way, the reason tetrahydrobiopterin (BH4) is so expensive, and without a prescription is only available in small dose tablets, is because BH4 was given orphan drug status in 2002, and this gives specific companies the exclusive right to sell BH4. Biomarin and Merck Serono have this right, and they sell their BH4 (trade name Kuvan) in 100 mg tablets.
However, this BH4 orphan drug status is due to expire in June 2015, ending the exclusivity, so thereafter we can expect the price of BH4 to drop, and the general availability and dosage amounts of BH4 to increase.